Clinical Trials
14 trialsNCT05438329 2026-05-12
First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors
DualityBio Inc.
Phase 1/2 Active not recruiting
NCT04896697 2026-05-05
Vilastobart (XTX101) Monotherapy and Vilastobart and Atezolizumab Combination Therapy in Advanced Solid Tumors
Xilio Development, Inc.
Phase 1/2 Active not recruiting
NCT06470763 2026-04-14
EXPAND-1
Anaveon AG
Phase 1/2 Active not recruiting
NCT06057922 2026-03-12
A Study YL201 in Patients With Selected Advanced Solid Tumors
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1/2 Active not recruiting
NCT05518045 2026-02-04
A Study of LM-108 as Monotherapy or in Combination With Antitumor Therapies in Subjects With Advanced Solid Tumors
LaNova Medicines Limited
Phase 1/2 Active not recruiting
NCT05744427 2026-02-02
Safety and Tolerability of JSKN003 in Chinese Subjects With Advanced Solid Tumors
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Phase 1/2 Active not recruiting
NCT04905914 2026-01-26
ABOYA-119
Aprea Therapeutics
Phase 1/2 Active not recruiting
NCT05163041 2026-01-15
Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression
BicycleTx Limited
Phase 1/2 Active not recruiting
NCT06345482 2025-11-20
A Study of MHB039A for Advanced Solid Tumor
Minghui Pharmaceutical (Hangzhou) Ltd
Phase 1/2 Active not recruiting
NCT06373406 2025-11-19
A Study of MHB036C for Advanced Solid Tumor
Minghui Pharmaceutical (Hangzhou) Ltd
Phase 1/2 Active not recruiting
NCT06260774 2025-10-02
Study of TTX-MC138 in Subjects With Advanced Solid Tumors
TransCode Therapeutics
Phase 1/2 Active not recruiting
NCT06480240 2025-08-08
A Phase 1/2 Study of OBI-992 in Subjects With Advanced Solid Tumors
OBI Pharma, Inc
Phase 1/2 Active not recruiting
NCT05990452 2024-11-21
Phase I/II FIH Study of 9MW2921 in Patients With Advanced Solid Tumors
Mabwell (Shanghai) Bioscience Co., Ltd.
Phase 1/2 Active not recruiting
NCT05765032 2024-09-26
Study of SHR-A1921 in Combination With Other Anti-cancer Agents in Patients With Advanced Solid Tumors
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 1/2 Active not recruiting